

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people [ID5104]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultation comments highlighted that the remit and population in the scope is restricted to people aged 1 to 17 years. It was suggested that this contributes to inequality based on age.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The remit and population in the scope reflects the population in the key clinical trial population and therefore the expected marketing authorisation for this indication. The committee is only able to make recommendations within the marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The remit was broadened to include all children and young people, without further age restriction.

|  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
| No.  |

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 04 August 2023